A Phase 2 interventional study of SHR-1209 in Familial Hypercholesterolemia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Status unknown. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-07-02.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The study is being conducted to evaluate the efficacy, safety and tolerability of SHR-1209 in subjects with familial hypercholesterolemia. 8 eligible patients (aged ≥18 years) with familial hypercholesterolemia, on stable maximum tolerable dose lipid-regulating therapy for at least 28 days, to receive subcutaneous SHR-1209, follow up 8 weeks. The primary endpoint was percentage change in LDL cholesterol from baseline at week 12 .
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
This study's planned enrollment of 8 is below the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Browse Hyperlipoproteinemia Type II studies →Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
Drug: SHR-1209
SHR-1209 administered by subcutaneous injection Atorvastatin or Rosuvastatin combined with Ezetimibe oral
Percent Change from Baseline in LDL-C at Week 12
Time frame: Week 12
Change From Baseline in LDL-C at Week 12
Time frame: Week 12
Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame: Weeks 10 and 12
Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
Time frame: Weeks 10 and 12
Percent Change From Baseline in the Total Cholesterol at the Mean of Weeks 10 and 12
Time frame: Weeks 10 and 12
Percent Change From Baseline in the Total Cholesterol at Week 12
Time frame: Week 12
Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12
Time frame: Weeks 10 and 12
Percent Change From Baseline in HDL-C at Week 12
Time frame: Week 12
Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12
Time frame: Weeks 10 and 12
Percent Change From Baseline in Non-HDL-C at Week 12
Time frame: Week 12
Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
Time frame: Weeks 10 and 12
Percent Change From Baseline in Triglycerides at Week 12
Time frame: Week 12
Percent Change From Baseline in Apo B at the Mean of Weeks 10 and 12
Time frame: Weeks 10 and 12
Percent Change From Baseline in ApoB at Week 12
Time frame: Week 12
Percent Change From Baseline in Apo A1 at the Mean of Weeks 10 and 12
Time frame: Weeks 10 and 12
Percent Change From Baseline in Apo A1 at Week 12
Time frame: Week 12
Percent Change From Baseline in Lipo(a) at the Mean of Weeks 10 and 12
Time frame: Weeks 10 and 12
Percent Change From Baseline in Lipo(a) at Week 12
Time frame: Week 12
Number of investigational product-related adverse events
Time frame: Weeks 12 and 20
Number of ADA and Nab
Time frame: Week 20
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2020; primary completion for Jun 2021, 9 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Recaticimab
Hyperlipoproteinemia Type II →
Jiangsu HengRui Medicine Co., Ltd. →